Tidal Investments LLC Purchases 13,179 Shares of Enliven Therapeutics, Inc. $ELVN

Tidal Investments LLC raised its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 27.7% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 60,694 shares of the company’s stock after acquiring an additional 13,179 shares during the period. Tidal Investments LLC’s holdings in Enliven Therapeutics were worth $3,080,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the company. KBC Group NV bought a new stake in Enliven Therapeutics in the 1st quarter valued at about $38,000. State of Wyoming purchased a new position in shares of Enliven Therapeutics in the second quarter worth about $96,000. FNY Investment Advisers LLC bought a new stake in shares of Enliven Therapeutics in the second quarter valued at approximately $126,000. Seven Fleet Capital Management LP purchased a new stake in shares of Enliven Therapeutics during the 4th quarter valued at approximately $180,000. Finally, Royal Bank of Canada boosted its holdings in Enliven Therapeutics by 345.0% in the 1st quarter. Royal Bank of Canada now owns 5,424 shares of the company’s stock worth $212,000 after buying an additional 4,205 shares during the period. Institutional investors own 95.08% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. The Goldman Sachs Group boosted their target price on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Guggenheim decreased their price objective on Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. JonesTrading raised their target price on Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Stifel Nicolaus lifted their target price on Enliven Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday, July 17th. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $75.00.

Enliven Therapeutics Price Performance

Shares of NASDAQ:ELVN opened at $53.36 on Wednesday. The firm has a fifty day moving average price of $56.53 and a two-hundred day moving average price of $45.75. Enliven Therapeutics, Inc. has a one year low of $14.78 and a one year high of $62.32. The company has a market cap of $3.91 billion, a price-to-earnings ratio of -31.95 and a beta of 0.30.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). Equities research analysts expect that Enliven Therapeutics, Inc. will post -1.69 EPS for the current fiscal year.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, Director Lori Kunkel sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $50.49, for a total value of $504,900.00. Following the sale, the director owned 41,884 shares of the company’s stock, valued at $2,114,723.16. This trade represents a 19.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $58.58, for a total value of $352,534.44. Following the completion of the sale, the chief financial officer directly owned 40,036 shares in the company, valued at approximately $2,345,308.88. The trade was a 13.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 180,831 shares of company stock valued at $10,735,269. Company insiders own 3.00% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for the treatment of cancer. The company applies a precision oncology approach, seeking to create targeted therapies that may offer improved efficacy, safety, durability and convenience compared with existing treatments.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven solid tumors.